User:Marikamoskalyk/sandbox

Proposed Change #1

When accounting for a person’s age, type of allergen, and severity of allergy, there is a high probability that subcutaneous AI may provide greater clinical and immunological responses than sublingual AI. Compared to sublingual AI, there are no significance differences observed in quality of life.

Proposed Change #2

Although efficacy of subcutaneous immunotherapy has been demonstrated by several studies,it entails the risk of systemic anaphylactic reactions. Hence the necessity for it to be performed by clinicians trained in allergy. ” It is possible, but rare (1/2.5 million), that people undergoing subcutaneous AI may experience a fatal anaphylactic event. However, subcutaneous AI adverse events vary significantly depending on different allergenic extracts and the application of different AI schedules (cluster, conventional, rush), so it is challenging to perform a risk assessment of the use of subcutaneous AI versus other forms of AI administration.

Comments
Thanks for sharing your proposed article improvements. I have a few notes: Great work so far! JenOttawa (talk) 03:22, 7 November 2018 (UTC)
 * Has “AI been defined earlier in the WP article? Verify.
 * Can you add wikilinks for some of the terms you are adding. The routes of administration, for example, and others.
 * I made a few adjustments to your sentence about fatal anaphylactic event. Just ideas though!
 * Make sure that your citations are consistently added after the punctuation like this.[1] (No spaces)
 * Can you find wikilinks to define the schedules? Is there a way to re-word this so people without a medical background can understand?